Literature DB >> 12876486

Tumor doubling time of cutaneous melanoma and its metastasis.

J Andrew Carlson1.   

Abstract

Tumor doubling time, estimated using clinical data, is one factor used to determine who will benefit from surgery for patients with pulmonary metastatic melanoma. Reported herein are the tumor doubling times of four primary cutaneous melanomas in which the diagnosis of melanoma had been delayed, and their metastases (3 of 4). The median/mean tumor doubling times for primary melanoma and metastatic melanoma was 94/144 days (range 50-377) and 33/64 days (range 8-212), respectively. By paired t test, metastatic tumor doubling time was significantly faster than primary tumor doubling time (P = 0.01). Extrapolating the growth curves of metastatic melanoma to the point of onset of metastasis revealed that dissemination of tumor cells occurred well before first clinical presentation and symptoms in two cases, and in one case, during the interval between clinical presentation and complete excision of the primary. At the opposite pole, extrapolated growth curves for slow tumor doubling time melanoma demonstrated that long-term follow up (>10 years) is required to determine whether patients have been cured of melanoma or not. Overall, these estimates of melanoma tumor doubling time validate the concept of tumor progression, reinforce the tenet of early detection and curative excision, and can explain the phenomenon of late onset of metastases, respectively.

Entities:  

Mesh:

Year:  2003        PMID: 12876486     DOI: 10.1097/00000372-200308000-00003

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  11 in total

1.  Optimal MRI interval for detection of asymptomatic recurrence in surgically treated early cervical cancer by use of a mathematical model.

Authors:  A Laios; K Gubbala; R Lampe; A Tolis
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

2.  Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach.

Authors:  Katherine Kay; Keith Dolcy; Robert Bies; Dhaval K Shah
Journal:  AAPS J       Date:  2019-02-08       Impact factor: 4.009

3.  Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.

Authors:  Eszter Szalai; Yi Jiang; Natasha M van Poppelen; Martine J Jager; Annelies de Klein; Emine Kilic; Hans E Grossniklaus
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

4.  Current concepts of metastasis in melanoma.

Authors:  Blazej Zbytek; J Andrew Carlson; Jacqueline Granese; Jeffrey Ross; Martin C Mihm; Andrzej Slominski
Journal:  Expert Rev Dermatol       Date:  2008-10

5.  Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Authors:  Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

6.  Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions.

Authors:  Evgeni V Nikolaev; Andrew Zloza; Eduardo D Sontag
Journal:  Front Immunol       Date:  2019-01-28       Impact factor: 7.561

7.  Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.

Authors:  Neta Tsur; Yuri Kogan; Evgenia Avizov-Khodak; Désirée Vaeth; Nils Vogler; Jochen Utikal; Michal Lotem; Zvia Agur
Journal:  J Transl Med       Date:  2019-10-07       Impact factor: 5.531

8.  Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.

Authors:  Tyler Cassidy; Morgan Craig
Journal:  PLoS Comput Biol       Date:  2019-11-27       Impact factor: 4.475

9.  Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses.

Authors:  Adarsh Kumbhari; Colt A Egelston; Peter P Lee; Peter S Kim
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

10.  Beyond the single average tumor: Understanding IO combinations using a clinical QSP model that incorporates heterogeneity in patient response.

Authors:  Rukmini Kumar; Kannan Thiagarajan; Lakshmanan Jagannathan; Liming Liu; Kapil Mayawala; Dinesh de Alwis; Brian Topp
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.